RGNX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RG

Mkt Cap

$456.9M

Volume

985.07K

Next Earnings

November 5th

Loading chart

RG

RGNXREGENXBIO Inc.

RGNX

Pay with—

Available Balance0.00

RG

Mkt Cap

$472.7M

Volume

985.07K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law FirmKuehn Law is investigating whether officers and directors of Regenxbio, Inc. breached fiduciary duties by providing false or misleading information about the efficacy and safety of RGX-111, a gene therapy for Hurler Syndrome. The firm is seeking shareholders who purchased stock prior to February 9, 2022.GlobeNewswire Inc. · Jul 13, 2026

Diabetic Retinopathy Pipeline Insight 2026: Comprehensive Analysis of 50+ Companies and 55+ Drugs in DevelopmentA comprehensive pipeline analysis reveals over 50 companies developing 55+ drugs for diabetic retinopathy treatment. Key developments include Kodiak Sciences' Tarcocimab tedromer (Phase III anti-VEGF therapy), Vantage Biosciences' VX-01 (Phase II oral treatment), and Therini Bio's THN391 (Phase I fibrin-targeting therapy). The report covers therapeutic assessments across various development stages, routes of administration, and molecule types, highlighting emerging opportunities in retinal disease treatment.GlobeNewswire Inc. · Jul 3, 2026

Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics LandscapeDelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Phase IIb/III trial initiation for MK-8748, 4D Molecular Therapeutics' Phase III enrollment completion for 4D-150, and FDA fast-track designation for SAR402663.GlobeNewswire Inc. · Jun 18, 2026

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNXREGENXBIO Inc. (NASDAQ: RGNX) faces a class action lawsuit for securities violations. The company allegedly made false and misleading statements about the safety and efficacy of its RGX-111 product candidate while concealing adverse information from investors. The FDA placed a clinical hold on RGX-111 after a clinical trial participant developed a tumor. Shareholders who purchased shares between February 9, 2022 and January 27, 2026 are encouraged to contact DJS Law Group regarding potential recovery.Benzinga · Apr 15, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNXPomerantz Law Firm has filed class action lawsuits against REGENXBIO Inc., AMC Entertainment Holdings, Inc., and Upstart Holdings, Inc. for alleged securities fraud and unlawful business practices. The REGENXBIO lawsuit was triggered by an FDA clinical hold on its gene therapy candidates RGX-111 and RGX-121, which caused the stock to fall 17.9% on January 28, 2026. Investors with losses are urged to contact the firm by the April 14, 2026 deadline to potentially serve as lead plaintiff.GlobeNewswire Inc. · Apr 14, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APEPomerantz Law Firm has filed class action lawsuits against AMC Entertainment Holdings, REGENXBIO Inc., and Upstart Holdings, alleging securities fraud and unlawful business practices. The AMC lawsuit specifically concerns APE preferred equity unit holders who were excluded from a special dividend following conversion to common stock due to an undisclosed loophole in the Certificate of Designations. Investors have until April 20, 2026, to request Lead Plaintiff status.GlobeNewswire Inc. · Apr 14, 2026

Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. InvestorsREGENXBIO investors can file a class action lawsuit for securities purchased between February 9, 2022 and January 27, 2026. The lawsuit alleges the company made false statements about the safety and efficacy of its RGX-111 gene therapy. On January 28, 2026, REGENXBIO announced the FDA placed a clinical hold on RGX-111 after an intraventricular CNS tumor was found in a trial participant, causing the stock to fall nearly 18%.GlobeNewswire Inc. · Apr 14, 2026

REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNXRosen Law Firm is reminding REGENXBIO investors who purchased securities between February 9, 2022 and January 27, 2026 of the April 14, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements about the efficacy and safety of its RGX-111 gene therapy trial while providing overwhelmingly positive public assertions, resulting in investor damages.GlobeNewswire Inc. · Apr 12, 2026

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against REGENXBIO Inc. alleging that the company made materially false and misleading statements regarding its RGX-111 gene therapy development and clinical trial results. The lawsuit covers investors who purchased securities between February 9, 2022 and January 27, 2026, with a lead plaintiff deadline of April 14, 2026.GlobeNewswire Inc. · Apr 6, 2026

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm is seeking lead plaintiffs for a securities fraud class action lawsuit against REGENXBIO Inc. The lawsuit alleges the company made false and misleading statements about its product candidate RGX-111, concealing negative efficacy and safety data while presenting overwhelmingly positive statements to investors. The fraud was allegedly revealed when an intraventricular CNS tumor was discovered in a study participant. Investors who purchased securities between February 9, 2022 and January 27, 2026 are encouraged to join the case.Benzinga · Apr 6, 2026

to start trading

RG

RGNXREGENXBIO Inc.

RGNX

Pay with—

Available Balance0.00

Your PositionYou don't own any RGNX yet.

Related Tickers

Earnings